COMPANY

Sofie

Keywords: CDMO services Gastrointestinal Cancers Cholangiocarcinoma Gastric Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma Hepatocellular Carcinoma Esophageal Cancer Gastroesophageal Junction PDAC - Pancreatic Ductal Adenocarcinoma [18F]FAPI-74 PET/CT [68Ga]FAPI-46

Location: Dulles, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Raises and deals from press releases

Raise Growth · amount not disclosed · announced Jun 4, 2024 Company release ↗
Source quote
- Jun 4, 2024 · Company release ↗
  “NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity firm, announced today that it has made a substantial growth investment in SOFIE Biosciences (“SOFIE” or the “Company”)”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Dec 11, 2025 Trial start Phase 3: Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) source ↗
Nov 14, 2025 Trial start Phase 3: Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. source ↗
Jun 4, 2024 Raise Growth · amount not disclosed source ↗
Apr 28, 2023 Trial start Phase 2: Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers source ↗
May 2, 2022 Trial start Phase 2: Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma source ↗

Upcoming milestones

Aug 30, 2027 (ESTIMATED) · Phase 3 · Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. · NCT07217704
Dec 31, 2027 (ESTIMATED) · Phase 3 · Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) · NCT07217717

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT05641896	Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers	Phase 2	Completed	Apr 28, 2023	Jun 30, 2025 (actual)
NCT07217717	Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 3	Recruiting	Dec 11, 2025	Dec 31, 2027 (estimated)
NCT07217704	Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.	Phase 3	Recruiting	Nov 14, 2025	Aug 30, 2027 (estimated)
NCT05262855	Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma	Phase 2	Completed	May 2, 2022	Mar 7, 2025 (actual)